TMC125-C211: Trial of TMC125 in HIV-1 Infected Subjects Who Were in a Sponsor Selected TMC125 Trial
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label, roll-over trial to evaluate the long term safety and
tolerability of TMC125, administered as part of an individually optimized antiretroviral
therapy, in HIV 1 infected subjects. In addition, the antiviral activity and immunological
effect of TMC125 as part of an antiretroviral regimen over time, and the evolution of HIV
phenotype and genotype will be evaluated.